Omeros Corp. (OMER)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$19.39+1.41%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Omeros expects positive cash flow by 2027, driven by the strong launch of YARTEMLEA. Revenue guidance ranges up to $2.1 billion by 2025, showing growth potential. Recent buybacks reduce debt and improve capital structure. The company beat earnings in Q1 2026, signaling operational progress.
Omeros remains loss-making with fragile quality and high risk. EPS is forecasted to be negative at -$0.27 next quarter and -$0.15 in 2027. Revenue estimates are low, around $17 million next quarter and $143 million in 2027. The recent 31% drawdown shows market skepticism about recovery.
The price is about 20% above our fair value near $8.4, reflecting optimism for turnaround and growth. However, consensus EPS and revenue estimates remain low and uncertain, suggesting the market may be pricing in a stronger recovery than visible.
Breaks if: no further buybacks or debt reduction announced
Breaks if: EPS remains negative or below $0.38 by FY26
Breaks if: fails to achieve positive cash flow by end of 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focusing on expanding its market presence and advancing its pipeline, which could lead to future growth.
The valuation indicates a premium compared to peers, suggesting that the market has high expectations for OMER's future performance. However, there is low fragility in the current setup, meaning that the stock is not overly sensitive to negative news at this time.
Management is on track with its priorities, particularly in launching YARTEMLEA and repurchasing convertible notes, which may stabilize the financial situation. However, the pipeline advancement is mixed, indicating some uncertainty in future developments.
The thesis hinges on the company's ability to maintain momentum in revenue growth and successfully advance its clinical pipeline. Additionally, external factors such as sector performance and economic conditions will play a significant role in shaping outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company reported a positive earnings beat. It achieved positive cash flow of $4.1 million in Q2 2026. There was a significant increase in market penetration and account growth. The company plans to expand its clinical pipeline with new studies. It is pursuing a re-examination of European marketing authorization for Yartemlia.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $0.34B by FY25
Over the next 1 to 3 years, OMER's performance will depend on its execution of strategic priorities and the broader healthcare sector's health. Not investment advice.